Search Results - "Bargagli, E."

Effects of rituximab therapy on B cell differentiation and depletion by Bergantini, L., d’Alessandro, M., Cameli, P., Vietri, L., Vagaggini, C., Perrone, A., Sestini, P., Frediani, B., Bargagli, E.

“…Rituximab is a human/murine chimeric anti-CD20 monoclonal antibody. It is largely used to treat B cell malignancies and has become standard in the management…”
Get full text

Oxidative stress in the pathogenesis of diffuse lung diseases: A review by Bargagli, E, Olivieri, C, Bennett, D, Prasse, A, Muller-Quernheim, J, Rottoli, P

“…Summary Oxidative stress is an imbalance between oxidants (reactive oxygen and nitrogen species) and antioxidants that may affect lipids, DNA, carbohydrates…”
Get full text

Prognostic bioindicators in severe COVID-19 patients by Bergantini, L., Bargagli, E., d'Alessandro, M., Refini, R.M., Cameli, P., Galasso, L., Scapellato, C., Montagnani, F., Scolletta, S., Franchi, F., Valente, S., Bennett, D., Sebastiani, G., Frediani, B., Dotta, F.

“…Severe acute respiratory syndrome caused by novel coronavirus 2 (SARS-CoV-2) emerged in Wuhan (China) in December 2019. Here we evaluated a panel of biomarkers…”
Get full text

Common molecular pathways targeted by nintedanib in cancer and IPF: A bioinformatic study by C, Landi, A, Carleo, L, Vantaggiato, L, Bergantini, d’Alessandro M, P, Cameli, G, Sebastiani, F, Dotta, E, Bargagli

“…Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease (ILD) sharing various genetic, molecular and cell processes with lung cancer (LC)…”
Get full text

Efficacy of pirfenidone for idiopathic pulmonary fibrosis: An Italian real life study by Harari, S, Caminati, A, Albera, C, Vancheri, C, Poletti, V, Pesci, A, Luppi, F, Saltini, C, Agostini, C, Bargagli, E, Sebastiani, A, Sanduzzi, A, Giunta, V, Della Porta, R, Bandelli, G.P, Puglisi, S, Tomassetti, S, Biffi, A, Cerri, S, Mari, A, Cinetto, F, Tirelli, F, Farinelli, G, Bocchino, M, Specchia, C, Confalonieri, M

“…Summary Background In this retrospective Italian study, which involved all major national interstitial lung diseases centers, we evaluated the effect of…”
Get full text

Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre by Bargagli, E., Piccioli, C., Rosi, E., Torricelli, E., Turi, L., Piccioli, E., Pistolesi, M., Ferrari, K., Voltolini, L.

“…Idiopathic pulmonary fibrosis has a median survival time after diagnosis of 2–5 years. The main goal of treating IPF is to stabilize or reduce the rate of…”
Get full text

NK and NKT-like cells in granulomatous and fibrotic lung diseases by Bergantini, L, Cameli, P, d’Alessandro, M, Vagaggini, C, Refini, RM, Landi, C, Pieroni, MG, Spalletti, M, Sestini, P, Bargagli, E

“…Abtract Background The pathogenetic and regulatory roles of natural killer (NK) and natural killer T-like cells in interstitial lung diseases (ILDs), fibrotic…”
Get full text

Incidence and risk factors for respiratory tract bacterial colonization and infection in lung transplant recipients by Paglicci, L., Borgo, V., Lanzarone, N., Fabbiani, M., Cassol, C., Cusi, MG, Valassina, M., Scolletta, S., Bargagli, E., Marchetti, L., Paladini, P., Luzzi, L., Fossi, A., Bennett, D., Montagnani, F.

“…To evaluate incidence of and risk factors for respiratory bacterial colonization and infections within 30 days from lung transplantation (LT). We…”
Get full text

Right cardiac involvement in lung diseases: a multimodality approach from diagnosis to prognostication by Mandoli, G. E., De Carli, G., Pastore, M. C., Cameli, P., Contorni, F., D’Alessandro, M., Bargagli, E., Mondillo, S., Cameli, M.

“…Lung diseases are amongst the main healthcare issues in the general population, having a high burden of morbidity and mortality. The cardiovascular system has…”
Get full text

Serum Analysis of Coagulation Factors in IPF and NSIP by Bargagli, E., Madioni, C., Bianchi, N., Refini, R. M., Cappelli, R., Rottoli, P.

“…Recent literature and our previous proteomic findings prompted us to study the coagulation system in idiopathic pulmonary fibrosis (IPF), the pathogenesis of…”
Get full text

A functional proteomics approach to the comprehension of sarcoidosis by Landi, C., Bargagli, E., Carleo, A., Bianchi, L., Gagliardi, A., Cillis, G., Perari, M.G., Refini, R.M., Prasse, A., Bini, L., Rottoli, P.

“…Pulmonary sarcoidosis (Sar) is an idiopathic disease histologically typified by non-caseating epitheliod cell sarcoid granulomas. A cohort of 37 Sar patients…”
Get full text

Differential redox proteomic profiles of serum from severe asthma patients after one month of benralizumab and mepolizumab treatment by Landi, C., Vantaggiato, L., Shaba, E., Cameli, P., Carleo, A., d’Alessandro, M., Bergantini, L., Bargagli, E., Bini, L.

“…Mepolizumab and Benralizumab are biological drugs for severe asthma patients able to reduce moderate-to-severe exacerbation rate (peripheral eosinophilial %…”
Get full text

Analysis of serum amyloid A in sarcoidosis patients by Bargagli, E, Magi, B, Olivieri, C, Bianchi, N, Landi, C, Rottoli, P

“…Summary A crucial pathogenetic role of serum amyloid A (SAA) in granulomatous inflammation of sarcoidosis has recently been reported. In this study we analyzed…”
Get full text

Collagen Type IV Alpha 5 Chain in Bronchiolitis Obliterans Syndrome After Lung Transplant: The First Evidence by Armati, M., Cattelan, S., Guerrieri, M., Messina, M., Perea, B., Genovese, M., d’Alessandro, M., Gangi, S., Cameli, P., Perillo, F., Bennett, D., Fossi, A., Bargagli, E., Bergantini, L.

“…Introduction Bronchiolitis obliterans syndrome (BOS) is the most common form of CLAD and is characterized by airflow limitation and an obstructive spirometry…”
Get full text

Exhaled nitric oxide in interstitial lung diseases by Cameli, P, Bargagli, E, Refini, R.M, Pieroni, M.G, Bennett, D, Rottoli, P

“…Highlights • We measure exhaled NO levels in patients with idiopathic interstitial pneumonias. • Patients have higher levels of exhaled NO than healthy…”
Get full text

Extracorporeal Photopheresis in Lung Transplantation by Bennett, D., Fossi, A., Ferrari, S., Lanzarone, N., Bargagli, E., Luzzi, L., Paladini, P., Rottoli, P., Sestini, P.

“…Extracorporeal photopheresis (ECP) is based on UV irradiation of peripheral leucocytes. It has been proposed for the treatment of chronic lung allograft…”
Get full text

Markers of Inflammation in Sarcoidosis: Blood, Urine, BAL, Sputum, and Exhaled Gas by Bargagli, E., MD, PhD, Mazzi, A., MD, Rottoli, Paola, MD

“…Sarcoidosis is characterized by intense inflammation at the different sites of localization. Many different mediators, such as cytokines, chemokines, and other…”
Get full text

Impact of interstitial lung disease on short-term and long-term survival of patients undergoing surgery for non-small-cell lung cancer: analysis of risk factors by Voltolini, Luca, Bongiolatti, Stefano, Luzzi, Luca, Bargagli, Elena, Fossi, Antonella, Ghiribelli, Claudia, Rottoli, Paola, Gotti, Giuseppe

“…OBJECTIVES The study aimed to determine the impact of interstitial lung disease (ILD) on postoperative morbidity, mortality and long-term survival of patients…”
Get full text

Combined sarcoidosis and idiopathic pulmonary fibrosis (CSIPF): A novel disease phenotype? by Bianchi, F., Piccioli, C., Rosi, E., Carobene, L., Spina, D., Mazzei, M.A., Bartolucci, M., Moroni, C., Novelli, L., Rottoli, P., Bargagli, E.

“…The association of these interstitial lung diseases (ILD) with different ethiopathogenesis and clinical course in a single patient is a real rare event, and…”
Get full text

Predictive role of natural killer cells in bronchoalveolar lavage fluid of patients with sarcoidosis by Bergantini, L, Spalletti, M, d'Alessandro, M, Genovese, M, Masotto, E, Cameli, P, Prasse, A, Bargagli, E

“…Sarcoidosis is a rare granulomatous disease of unknown aetiology belonging to the wide group of interstitial lung diseases.). Although the limitlessness of BAL…”
Get full text